ArticlePharmaceuticals (Basel, Switzerland)2025

Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients.

Marc Bertaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.